Home » Advanced Materials » U.S. Biomaterials Market

U.S. Biomaterials Market

U.S. Biomaterials Market By Product Type (Metallic [Stainless Steel, Gold, Magnesium, Silver, Others], Ceramic [Aluminum Oxide, Calcium Sulfate, Carbon, Glass, Others], Polymer [Polymethylmethacrylate, Polyethylene, Polyester, Nylon, Others], Natural [Hyaluronic Acid, Collagen, Gelatin, Fibrin and Others], Others); By Application (Cardiovascular, Orthopedics, Plastic Surgery, Ophthalmology, Dental, Neurology, Tissue Engineering, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
U.S. Biomaterials Market Size 2024	USD 64,865.73 million
U.S. Biomaterials Market, CGR	15.02%
U.S. Biomaterials Market Size 2032	USD 1,98,681.66 million

Market Overview

U.S. Biomaterials market size was valued at USD 64,865.73 million in 2024 and is anticipated to reach USD 1,98,681.66 million by 2032, at a CAGR of 15.02% during the forecast period (2024-2032).

The U.S. biomaterials market is driven by several key factors, including the growing demand for advanced medical treatments, an aging population, and increasing healthcare expenditures. Technological advancements in biomaterial science, such as the development of biocompatible materials for implants and prosthetics, have significantly boosted market growth. The rising prevalence of chronic diseases, orthopedic disorders, and dental issues further fuels demand for specialized biomaterials. Additionally, the expansion of the healthcare sector, coupled with a rising focus on personalized medicine, is shaping the market’s future. Key trends include the increasing use of bioresorbable materials, 3D printing in medical applications, and innovations in regenerative medicine. Government initiatives supporting research and development, alongside the continuous integration of nanotechnology, are also contributing to the market’s expansion. As the healthcare industry continues to evolve, the demand for innovative and sustainable biomaterials is expected to rise steadily over the coming years.

The geographical landscape of the U.S. biomaterials market is shaped by the presence of innovation hubs, advanced healthcare infrastructure, and regional investment in medical research. The Western U.S. leads in technological innovation, supported by prominent biotech firms and research institutions, while the Midwest serves as a manufacturing and healthcare stronghold with established medical device companies. The Southern region is experiencing rapid growth due to increasing healthcare demand and favorable business conditions, and the Northeast remains a center for biomedical research and academic excellence. Key players driving the U.S. biomaterials market include industry leaders such as Johnson & Johnson, Baxter International, Biomet, Smith & Nephew, and Stryker. These companies play a crucial role in advancing biomaterial technologies through continuous research, strategic partnerships, and product innovation. Their extensive product portfolios and strong distribution networks enable them to meet the evolving demands across various medical applications, from orthopedics and cardiovascular care to tissue engineering and dental solutions.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The U.S. biomaterials market was valued at USD 64,865.73 million in 2024 and is projected to reach USD 198,681.66 million by 2032, growing at a CAGR of 15.02%.

The global biomaterials market was valued at USD 2,03,827.80 million in 2024 and is projected to reach USD 6,19,828.57 million by 2032, growing at a CAGR of 14.91% during the forecast period.

Increasing demand for advanced medical treatments and an aging population are key drivers fueling market growth.
Technological advancements such as 3D printing, bioresorbable materials, and nanotechnology are shaping product innovation.
Major players like Johnson & Johnson, Stryker, and Baxter International maintain a competitive edge through extensive R&D and diversified portfolios.
High production costs and complex regulatory approval processes pose challenges for new entrants and innovation scalability.
The Western U.S. leads in innovation, the Midwest in manufacturing, the South in demand growth, and the Northeast in research excellence.
The integration of biomaterials in regenerative medicine and minimally invasive procedures offers new growth avenues across medical fields.

Report Scope

This report segments the U.S. Biomaterials Market as follows:

Market Drivers

Aging Population and Growing Healthcare Needs

One of the primary drivers of the U.S. biomaterials market is the aging population, which is creating a heightened demand for medical solutions that address age-related health conditions. For instance, the U.S. biomaterials market is expanding due to the rising demand for medical interventions such as implants, prosthetics, and joint replacements. Biomaterials, including those used in orthopedic implants, dental procedures, and cardiovascular devices, are essential for improving the quality of life for elderly patients. The aging demographic is also contributing to an increase in chronic conditions, such as arthritis, heart disease, and diabetes, further boosting demand for advanced biomaterials in medical treatments. This trend is expected to continue over the forecast period, significantly driving market growth.

Advancements in Medical Technology

Technological innovations in the field of biomaterials are another significant factor propelling market growth. Over the past decade, there have been substantial advancements in biomaterial science, resulting in more effective and durable products for medical applications. These advancements include the development of biocompatible, bioresorbable, and bioactive materials that are tailored to meet the specific needs of patients. For instance, bioresorbable polymers are increasingly being used in drug delivery systems and tissue regeneration applications, reducing the need for surgical removal. Additionally, the integration of nanotechnology has enhanced the properties of biomaterials, improving their performance in complex medical procedures. As the demand for precision medicine and personalized healthcare solutions increases, the continuous evolution of biomaterial technologies will play a crucial role in the market’s expansion.

Growing Prevalence of Chronic Diseases and Disorders

The rising incidence of chronic diseases and disorders is another key driver for the U.S. biomaterials market. Conditions such as cardiovascular diseases, diabetes, orthopedic disorders, and dental problems are becoming more prevalent, especially among the aging population. Biomaterials are increasingly being used to treat these conditions, particularly in the form of implants, prosthetics, and other medical devices. For example, biomaterials are widely used in the development of stents, pacemakers, joint replacements, and dental implants. The growing demand for these medical interventions is expected to continue as the number of individuals affected by chronic diseases increases. Additionally, the focus on improving patient outcomes through minimally invasive procedures further supports the use of biomaterials in various medical treatments.

Government Support and Research Investments

Government initiatives and investments in research and development are playing a crucial role in driving the growth of the U.S. biomaterials market. Federal agencies, such as the National Institutes of Health (NIH), provide significant funding for research aimed at developing innovative biomaterials and improving existing technologies. The U.S. government has also established policies that support the commercialization of medical technologies, including biomaterials. These initiatives are encouraging collaboration between academic institutions, research organizations, and private companies, resulting in faster advancements in biomaterial science. Additionally, regulatory agencies like the U.S. Food and Drug Administration (FDA) are actively working to streamline the approval process for new biomaterial-based products, further accelerating market growth. The continued support from the government will likely ensure the sustained expansion of the biomaterials market over the coming years.

Market Trends

Shift Toward Bioresorbable Materials

A prominent trend in the U.S. biomaterials market is the increasing adoption of bioresorbable materials, which are designed to gradually degrade and be absorbed by the body over time. These materials are particularly valuable in applications like drug delivery systems, sutures, and implants, where the need for permanent materials is not necessary. For instance, bioresorbable polymers like polylactic acid (PLA) and poly(lactic-co-glycolic acid) (PLGA) are increasingly used in drug delivery systems, sutures, and implants. This trend is driven by the growing demand for minimally invasive procedures and the desire for more sustainable, patient-friendly treatments. As the technology improves, bioresorbable materials are expected to be used in a broader range of applications, contributing to market expansion.

3D Printing and Customization in Biomaterials

The integration of 3D printing technologies into biomaterial manufacturing is a rapidly growing trend that is transforming the landscape of medical devices and implants. For instance, 3D printing is revolutionizing biomaterials manufacturing by enabling highly customized implants and prosthetics. 3D printing allows for the creation of highly customized, patient-specific biomaterials tailored to individual anatomical needs. By using 3D printing techniques, manufacturers can produce more complex structures that offer improved functionality and better integration with human tissue. The ability to rapidly prototype and test new biomaterials has also accelerated innovation in the industry, leading to faster product development cycles. As 3D printing continues to advance, its role in the biomaterials market is expected to expand, offering patients more personalized and effective treatment options.

Focus on Regenerative Medicine

Regenerative medicine is a key trend in the U.S. biomaterials market, driven by the growing interest in tissue engineering and stem cell therapies. Biomaterials play a crucial role in the development of scaffolds and matrices that support cell growth and tissue regeneration. These materials are used in applications ranging from wound healing and bone repair to the regeneration of more complex tissues such as cartilage, skin, and nerves. Advances in stem cell research and tissue engineering are creating new opportunities for biomaterials to assist in the restoration of damaged or diseased tissues. As research in regenerative medicine progresses, the demand for specialized biomaterials that can support tissue regeneration and healing will continue to rise, positioning this sector as a major trend in the industry.

Sustainability and Eco-Friendly Biomaterials

As environmental concerns continue to grow, there is an increasing emphasis on sustainability in the biomaterials market. Manufacturers are focusing on developing eco-friendly biomaterials that not only meet the technical requirements for medical applications but also have a reduced environmental impact. This includes the use of biodegradable polymers, renewable resources, and green manufacturing processes that minimize waste and energy consumption. The shift towards more sustainable biomaterials is particularly relevant in the context of rising public awareness about climate change and the need for responsible consumption. Additionally, regulatory pressure to reduce the carbon footprint of medical devices is expected to drive further innovation in this area. As sustainability becomes a higher priority in healthcare, the demand for eco-friendly biomaterials is anticipated to grow, influencing market trends in the coming years.

Market Challenges Analysis

High Production Costs and Complex Manufacturing Processes

One of the major challenges facing the U.S. biomaterials market is the high cost of production and the complex manufacturing processes associated with biomaterial products. The development of advanced biomaterials often requires significant investment in research, testing, and regulatory approvals. Moreover, the materials used in specialized medical applications, such as biocompatible polymers and bioresorbable materials, can be expensive to produce. Additionally, the manufacturing processes involved in creating these materials often require sophisticated equipment, skilled labor, and strict quality control, all of which contribute to high production costs. These factors make it difficult for smaller manufacturers to enter the market, while larger companies face pressure to maintain cost efficiency without compromising on quality. The challenge of balancing innovation with cost containment remains a significant barrier for many players in the biomaterials sector.

Regulatory Hurdles and Approval Delays

The regulatory landscape for biomaterials presents another challenge in the U.S. market. For instance, biomaterials are subject to strict oversight by regulatory agencies such as the FDA, requiring extensive clinical data for approval. However, the approval process for biomaterials can be lengthy and costly, particularly for novel or complex materials. Manufacturers must provide extensive clinical data to support the safety and performance of their products, which can delay time-to-market and increase development costs. Additionally, evolving regulatory requirements and standards can introduce further uncertainties for companies, as they must constantly adapt to new guidelines and compliance measures. These regulatory hurdles can slow innovation and hinder the growth of the biomaterials market, especially for smaller companies with limited resources.

Market Opportunities

The U.S. biomaterials market presents significant opportunities driven by the increasing demand for advanced medical solutions and innovations in material science. As the population ages and chronic diseases become more prevalent, the need for effective and long-lasting medical implants, prosthetics, and regenerative therapies continues to grow. This creates opportunities for manufacturers to develop next-generation biomaterials that are more durable, biocompatible, and tailored to patient-specific needs. The growing focus on personalized medicine is encouraging the use of custom biomaterial-based solutions, particularly in orthopedics, cardiovascular treatments, and dental care. Additionally, advancements in 3D printing technology allow for greater customization and faster prototyping of implants and scaffolds, accelerating innovation and expanding the potential for niche and patient-centered applications.

Another major opportunity lies in the field of regenerative medicine and tissue engineering, where biomaterials serve as essential scaffolding for cellular growth and tissue regeneration. The integration of biomaterials with stem cell therapies and biologics offers promising prospects for healing damaged tissues and organs, creating a fertile ground for research and commercialization. Moreover, the rising interest in minimally invasive surgical procedures is driving the development of bioresorbable and injectable biomaterials, which can enhance recovery times and reduce complications. Government funding and supportive regulatory frameworks are further enabling innovation, particularly in eco-friendly and biodegradable biomaterials that align with sustainability goals. As healthcare providers seek safer, more efficient, and cost-effective solutions, companies that can innovate and adapt to evolving clinical needs are well-positioned to capitalize on these emerging opportunities within the U.S. biomaterials market.

Market Segmentation Analysis:

By Product Type:

The U.S. biomaterials market is segmented into metallic, ceramic, polymer, natural, and other types, each serving distinct roles in various medical applications. Metallic biomaterials, including stainless steel, gold, magnesium, silver, and others, are widely used in orthopedic implants, dental applications, and cardiovascular devices due to their high strength, durability, and biocompatibility. Among these, stainless steel and titanium alloys remain dominant due to their extensive use in joint replacements and fracture fixation devices. Ceramic biomaterials such as aluminum oxide, calcium sulfate, carbon, and glass offer excellent wear resistance and are commonly used in dental and orthopedic implants. Polymers, including polymethylmethacrylate (PMMA), polyethylene, polyester, and nylon, are valued for their flexibility, lightweight nature, and compatibility with soft tissues, making them ideal for applications in ophthalmology and drug delivery. Natural biomaterials like hyaluronic acid, collagen, gelatin, and fibrin are gaining traction for their use in regenerative medicine and tissue engineering, driven by their bioactivity and minimal immune response. This diverse material landscape supports innovation across a wide spectrum of healthcare applications.

By Application:

The application landscape of the U.S. biomaterials market encompasses cardiovascular, orthopedics, plastic surgery, ophthalmology, dental, neurology, tissue engineering, and other medical fields. Cardiovascular applications represent a significant share, with biomaterials used in stents, heart valves, and vascular grafts to treat a rising number of heart-related conditions. Orthopedics remains a major segment, with high demand for joint replacements and spinal implants fueled by an aging population and increased sports-related injuries. In plastic surgery, biomaterials enhance reconstructive procedures, while in ophthalmology, they are essential for intraocular lenses and corneal implants. Dental applications benefit from biomaterials in implants, crowns, and bridges, offering durable and aesthetic solutions. Neurology utilizes biomaterials in neural repair and stimulation devices, with growing interest in treatments for neurodegenerative disorders. Tissue engineering is emerging as a transformative field, with biomaterials playing a central role in developing scaffolds and matrices for cell growth and regeneration. As medical technologies evolve, biomaterials continue to support advancements across these diverse and critical healthcare applications.

Segments:

Based on Product Type:

Metallic
Stainless Steel
Gold
Magnesium
Silver
Others
Ceramic
Aluminum Oxide
Calcium Sulfate
Carbon
Glass
Others
Polymer
Polymethylmethacrylate
Polyethylene
Polyester
Nylon
Others
Natural
Hyaluronic Acid
Collagen
Gelatin
Fibrin and others
Others

Based on Application:

Cardiovascular
Orthopedics
Plastic Surgery
Ophthalmology
Dental
Neurology
Tissue Engineering
Others

Based on the Geography:

Western United States
Midwestern United States
Southern United States
Northeastern United States

Regional Analysis

Western United States

The Western United States holds the largest share of the U.S. biomaterials market, accounting for approximately 32% of the total market in 2024. This dominance is largely driven by the region’s concentration of leading biotechnology and medical device companies, particularly in California, which is home to Silicon Valley’s thriving health tech ecosystem. The presence of premier research institutions and innovation hubs fosters a favorable environment for biomaterial development and commercialization. Additionally, the Western region benefits from strong venture capital activity and government-backed research initiatives that support advanced material science and healthcare innovation. With an emphasis on technological integration and sustainable healthcare solutions, the Western U.S. continues to lead in the adoption of next-generation biomaterials across applications such as orthopedics, cardiovascular devices, and regenerative medicine.

Midwestern United States

The Midwestern United States represents approximately 26% of the U.S. biomaterials market and plays a critical role due to its robust manufacturing base and strong healthcare infrastructure. States like Minnesota, Illinois, and Ohio have established themselves as centers for medical device production and research, making the Midwest a key contributor to the biomaterials industry. The presence of major hospitals, research universities, and healthcare systems drives demand for innovative biomaterial-based solutions, particularly in orthopedics and cardiovascular applications. Furthermore, the region’s focus on affordability and operational efficiency has encouraged the development of cost-effective biomaterials suitable for large-scale application. The Midwest continues to attract investment in medical research, supporting the advancement of biocompatible and bioresorbable materials for clinical use.

Southern United States

The Southern United States holds around 23% of the U.S. biomaterials market, driven by population growth, rising healthcare needs, and an expanding medical device industry. States such as Texas and Florida are experiencing increased demand for biomaterials due to their large and aging populations, as well as higher incidences of chronic diseases. The Southern region is also seeing increased investment in healthcare infrastructure, with several academic medical centers and innovation clusters promoting biomaterials research. This region is particularly active in areas such as dental biomaterials and wound care, where the need for cost-effective, high-performance materials is rising. Additionally, favorable business climates and tax incentives have made the South an attractive destination for manufacturers and developers in the biomaterials space.

Northeastern United States

The Northeastern United States accounts for approximately 19% of the market and is a critical region due to its concentration of prestigious medical schools, research institutions, and pharmaceutical companies. States like Massachusetts, New York, and Pennsylvania are known for their innovation in biomedical sciences and are instrumental in pushing forward the development of advanced biomaterials. The Northeast is particularly strong in the fields of tissue engineering and regenerative medicine, with institutions conducting cutting-edge research into novel biomaterials for use in neurology, ophthalmology, and plastic surgery. While the region may have a smaller market share compared to others, it plays a vital role in setting trends and driving high-value innovation in the U.S. biomaterials landscape.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Johnson & Johnson
Baxter International
Biomet
Smith & Nephew
Stryker

Competitive Analysis

The competitive landscape of the U.S. biomaterials market is characterized by the presence of several prominent players, including Johnson & Johnson, Baxter International, Biomet, Smith & Nephew, and Stryker. These companies maintain a strong market position through extensive research and development, strategic partnerships, and diversified product offerings across various medical applications such as orthopedics, cardiovascular, dental, and tissue engineering. Leading companies focus heavily on research and development to create high-performance biomaterials tailored for a wide range of medical applications, including orthopedics, cardiovascular care, dental procedures, and regenerative medicine. Strategic initiatives such as mergers and acquisitions, product launches, and collaborations with research institutions are commonly employed to enhance market presence and accelerate innovation. Firms in this space also prioritize the development of bioresorbable and patient-specific materials, aligning with the growing demand for minimally invasive and personalized medical treatments. Strong distribution networks and a robust regulatory understanding further support market penetration and product adoption. Despite intense competition, the market continues to offer opportunities for differentiation through novel biomaterials, sustainability-driven innovations, and targeted applications in emerging therapeutic areas. The ability to adapt to evolving clinical needs and maintain compliance with regulatory standards remains crucial for sustaining a competitive edge.

Recent Developments

In April 2025, BASF expanded its EcoBalanced portfolio for Care Chemicals in North America, introducing the first EcoBalanced personal care products in the region. These include Dehyton® PK 45 and Dehyton® KE UP, both certified as EcoBalanced grades using a biomass balance (BMB) approach to reduce carbon footprint. Additionally, six U.S. Care Chemicals production sites are now powered entirely by renewable electricity, saving approximately 33,000 tons of CO₂ annually.
In November 2024, Covestro began production of Desmophen® CQ NH, a partially bio-based polyaspartic resin (at least 25% bio-based content), at its Foshan, China site. The facility is powered entirely by renewable energy, and the product is used in wind turbine and flooring coatings, supporting both local supply and sustainability goals.
In January 2025, BASF’s Performance Materials division transitioned all European sites to 100% renewable electricity, covering engineering plastics, polyurethanes, thermoplastic polyurethanes, and specialty polymers.
In June 2023, Invibio announced a collaboration with Paragon Medical to scale up manufacturing of PEEK-OPTIMA Ultra-Reinforced composite trauma devices in China, responding to growing global demand for high-performance biomaterials in trauma fixation.
In February 2023, Celanese introduced ECO-B, more sustainable versions of Acetyl Chain materials, incorporating mass balance bio-content to provide chemically identical, bio-based alternatives for engineered materials.

Market Concentration & Characteristics

The U.S. biomaterials market exhibits moderate to high concentration, dominated by a few key players that command significant market share through extensive product portfolios, strong brand recognition, and global distribution networks. These companies invest heavily in research and development, continuously advancing biomaterial technologies to meet the growing demand for innovative medical solutions. The market is characterized by a mix of well-established multinational corporations and emerging companies focusing on niche biomaterial applications. Competitive dynamics are influenced by factors such as technological innovation, regulatory compliance, and cost-effectiveness. Additionally, the market is marked by ongoing collaborations between biomaterial manufacturers, healthcare providers, and academic institutions, driving the development of next-generation materials. The industry’s characteristics also reflect a growing emphasis on sustainable and bioresorbable materials, as well as personalized medical treatments, which are reshaping the landscape and fostering new opportunities for market players. Overall, the market remains dynamic and evolving, with a constant focus on innovation and patient-centered solutions.

Report Coverage

The research report offers an in-depth analysis based on Product Type, Application and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The U.S. biomaterials market is expected to grow significantly due to advancements in regenerative medicine and tissue engineering.
Rising demand for biocompatible materials in medical devices, implants, and drug delivery systems will continue to drive market expansion.
Innovations in nanotechnology are anticipated to enhance the functionality and precision of biomaterials.
The integration of 3D printing technology in biomaterial development will enable highly customized and patient-specific solutions.
Regulatory advancements will likely streamline the approval process for new biomaterials, accelerating market growth.
Biodegradable and eco-friendly biomaterials will see increased demand due to growing environmental concerns and sustainability initiatives.
The aging population in the U.S. will contribute to the increasing need for biomaterials in orthopedic and dental implants.
Collaborations between research institutions and industry leaders will foster breakthroughs in advanced biomaterials.
Personalized medicine will drive the demand for biomaterials tailored to individual genetic profiles and medical needs.
Investment in biomaterial research and development is expected to increase, leading to new products and technologies in the healthcare sector.

CHAPTER NO. 1 : INTRODUCTION 18

1.1.1. Report Description 18

Purpose of the Report 18

USP & Key Offerings 18

1.1.2. Key Benefits for Stakeholders 18

1.1.3. Target Audience 19

1.1.4. Report Scope 19

CHAPTER NO. 2 : EXECUTIVE SUMMARY 20

2.1. U.S. Biomaterials Market Snapshot 20

2.1.1. U.S. Biomaterials Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : U.S. BIOMATERIALS MARKET – INDUSTRY ANALYSIS 23

3.1. Introduction 23

3.2. Market Drivers 24

3.2.1. Advancements in Regenerative Medicine and Tissue Engineering 24

3.2.2. Increased Demand for Minimally Invasive Surgical Procedures 25

3.3. Market Restraints 26

3.3.1. Regulatory Challenges and Approval Delays of the Products 26

3.4. Market Opportunities 27

3.4.1. Market Opportunity Analysis 27

3.5. Porter’s Five Forces Analysis 28

CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE 29

4.1. Company Market Share Analysis – 2024 29

4.1.1. U.S. Biomaterials Market: Company Market Share, by Volume, 2024 29

4.1.2. U.S. Biomaterials Market: Company Market Share, by Revenue, 2024 30

4.1.3. U.S. Biomaterials Market: Top 6 Company Market Share, by Revenue, 2024 30

4.1.4. U.S. Biomaterials Market: Top 3 Company Market Share, by Revenue, 2024 31

4.2. U.S. Biomaterials Market Company Revenue Market Share, 2024 32

4.3. Company Assessment Metrics, 2024 33

4.3.1. Stars 33

4.3.2. Emerging Leaders 33

4.3.3. Pervasive Players 33

4.3.4. Participants 33

4.4. Start-ups /SMEs Assessment Metrics, 2024 33

4.4.1. Progressive Companies 33

4.4.2. Responsive Companies 33

4.4.3. Dynamic Companies 33

4.4.4. Starting Blocks 33

4.5. Strategic Developments 34

4.5.1. Acquisitions & Mergers 34

New Product Launch 34

U.S. Expansion 34

4.6. Key Players Product Matrix 35

CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS 36

5.1. PESTEL 36

5.1.1. Political Factors 36

5.1.2. Economic Factors 36

5.1.3. Social Factors 36

5.1.4. Technological Factors 36

5.1.5. Environmental Factors 36

5.1.6. Legal Factors 36

5.2. Adjacent Market Analysis 36

CHAPTER NO. 6 : U.S. BIOMATERIALS MARKET – BY PRODUCT TYPE SEGMENT ANALYSIS 37

6.1. U.S. Biomaterials Market Overview, by Product Type Segment 37

6.1.1. U.S. Biomaterials Market Revenue Share, By Product Type, 2023 & 2032 38

6.1.2. U.S. Biomaterials Market Attractiveness Analysis, By Product Type 39

6.1.3. Incremental Revenue Growth Opportunity, by Product Type, 2024 – 2032 39

6.1.4. U.S. Biomaterials Market Revenue, By Product Type, 2018, 2023, 2027 & 2032 40

6.2. Metallic 41

6.3. Stainless Steel 42

6.4. Gold 43

6.5. Magnesium 44

6.6. Silver 45

6.7. Others 46

6.8. Ceramic 47

6.9. Aluminum Oxide 48

6.10. Calcium Sulfate 49

6.11. Carbon 50

6.12. Glass 51

6.13. Others 52

6.14. Polymer 53

6.15. Polymethylmethacrylate 54

6.16. Polyethylene 55

6.17. Polyester 56

6.18. Nylon 57

6.19. Others 58

6.20. Natural 59

6.21. Hyaluronic Acid 60

6.22. Collagen 61

6.23. Gelatin 62

6.24. Fibrin 63

6.25. Others 64

6.26. Others 65

CHAPTER NO. 7 : U.S. BIOMATERIALS MARKET – BY APPLICATION SEGMENT ANALYSIS 66

7.1. U.S. Biomaterials Market Overview, by Application Segment 66

7.1.1. U.S. Biomaterials Market Revenue Share, By Application, 2023 & 2032 67

7.1.2. U.S. Biomaterials Market Attractiveness Analysis, By Application 68

7.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 68

7.1.4. U.S. Biomaterials Market Revenue, By Application, 2018, 2023, 2027 & 2032 69

7.2. Cardiovascular 70

7.3. Orthopedics 71

7.4. Plastic Surgery 72

7.5. Ophthalmology 73

7.6. Dental 74

7.7. Neurology 75

7.8. Tissue Engineering 76

7.9. Others 77

CHAPTER NO. 8 : U.S. BIOMATERIALS MARKET – U.S. ANALYSIS 78

8.1. Product Type 78

8.1.1. U.S. Biomaterials Market Revenue, By Product Type, 2018 – 2023 (USD Million) 78

8.1.2. U.S. Biomaterials Market Revenue, By Product Type, 2024 – 2032 (USD Million) 78

8.2. Application 79

8.2.1. U.S. Biomaterials Market Revenue, By Application, 2018 – 2023 (USD Million) 79

8.2.2. U.S. Biomaterials Market Revenue, By Application, 2024 – 2032 (USD Million) 79

CHAPTER NO. 9 : COMPANY PROFILES 80

9.1. Johnson & Johnson 80

9.1.1. Company Overview 80

9.1.2. Product Portfolio 80

9.1.3. Swot Analysis 80

9.1.4. Business Strategy 81

9.1.5. Financial Overview 81

9.2. Baxter International 82

9.3. Biomet 82

9.4. Smith & Nephew 82

9.5. Stryker 82

9.6. Company 6 82

9.7. Company 7 82

9.8. Company 8 82

9.9. Company 9 82

9.10. Company 10 82

9.11. Company 11 82

9.12. Company 12 82

9.13. Company 13 82

9.14. Company 14 8

List of Figures

FIG NO. 1. U.S. Biomaterials Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for U.S. Biomaterials Market 28

FIG NO. 3. Company Share Analysis, 2024 29

FIG NO. 4. Company Share Analysis, 2024 30

FIG NO. 5. Company Share Analysis, 2024 30

FIG NO. 6. Company Share Analysis, 2024 31

FIG NO. 7. U.S. Biomaterials Market – Company Revenue Market Share, 2024 32

FIG NO. 8. U.S. Biomaterials Market Revenue Share, By Product Type, 2023 & 2032 38

FIG NO. 9. Market Attractiveness Analysis, By Product Type 39

FIG NO. 10. Incremental Revenue Growth Opportunity by Product Type, 2024 – 2032 39

FIG NO. 11. U.S. Biomaterials Market Revenue, By Product Type, 2018, 2023, 2027 & 2032 40

FIG NO. 12. U.S. Biomaterials Market for Metallic, Revenue (USD Million) 2018 – 2032 41

FIG NO. 13. U.S. Biomaterials Market for Stainless Steel, Revenue (USD Million) 2018 – 2032 42

FIG NO. 14. U.S. Biomaterials Market for Gold, Revenue (USD Million) 2018 – 2032 43

FIG NO. 15. U.S. Biomaterials Market for Magnesium, Revenue (USD Million) 2018 – 2032 44

FIG NO. 16. U.S. Biomaterials Market for Cooling Silver, Revenue (USD Million) 2018 – 2032 45

FIG NO. 17. U.S. Biomaterials Market for Others, Revenue (USD Million) 2018 – 2032 46

FIG NO. 18. U.S. Biomaterials Market for Ceramic, Revenue (USD Million) 2018 – 2032 47

FIG NO. 19. U.S. Biomaterials Market for Cooling Aluminum Oxide, Revenue (USD Million) 2018 – 2032 48

FIG NO. 20. U.S. Biomaterials Market for Calcium Sulfate, Revenue (USD Million) 2018 – 2032 49

FIG NO. 21. U.S. Biomaterials Market for Carbon, Revenue (USD Million) 2018 – 2032 50

FIG NO. 22. U.S. Biomaterials Market for Glass, Revenue (USD Million) 2018 – 2032 51

FIG NO. 23. U.S. Biomaterials Market for Others, Revenue (USD Million) 2018 – 2032 52

FIG NO. 24. U.S. Biomaterials Market for Polymer, Revenue (USD Million) 2018 – 2032 53

FIG NO. 25. U.S. Biomaterials Market for Polymethylmethacrylate, Revenue (USD Million) 2018 – 2032 54

FIG NO. 26. U.S. Biomaterials Market for Polyethylene, Revenue (USD Million) 2018 – 2032 55

FIG NO. 27. U.S. Biomaterials Market for Polyester, Revenue (USD Million) 2018 – 2032 56

FIG NO. 28. U.S. Biomaterials Market for Nylon, Revenue (USD Million) 2018 – 2032 57

FIG NO. 29. U.S. Biomaterials Market for Others, Revenue (USD Million) 2018 – 2032 58

FIG NO. 30. U.S. Biomaterials Market for Natural, Revenue (USD Million) 2018 – 2032 59

FIG NO. 31. U.S. Biomaterials Market for Hyaluronic Acid, Revenue (USD Million) 2018 – 2032 60

FIG NO. 32. U.S. Biomaterials Market for Collagen, Revenue (USD Million) 2018 – 2032 61

FIG NO. 33. U.S. Biomaterials Market for Gelatin, Revenue (USD Million) 2018 – 2032 62

FIG NO. 34. U.S. Biomaterials Market for Fibrin, Revenue (USD Million) 2018 – 2032 63

FIG NO. 35. U.S. Biomaterials Market for Others, Revenue (USD Million) 2018 – 2032 64

FIG NO. 36. U.S. Biomaterials Market for Others, Revenue (USD Million) 2018 – 2032 65

FIG NO. 37. U.S. Biomaterials Market Revenue Share, By Application, 2023 & 2032 67

FIG NO. 38. Market Attractiveness Analysis, By Application 68

FIG NO. 39. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 68

FIG NO. 40. U.S. Biomaterials Market Revenue, By Application, 2018, 2023, 2027 & 2032 69

FIG NO. 41. U.S. Biomaterials Market for Cardiovascular, Revenue (USD Million) 2018 – 2032 70

FIG NO. 42. U.S. Biomaterials Market for Orthopedics, Revenue (USD Million) 2018 – 2032 71

FIG NO. 43. U.S. Biomaterials Market for Plastic Surgery, Revenue (USD Million) 2018 – 2032 72

FIG NO. 44. U.S. Biomaterials Market for Ophthalmology, Revenue (USD Million) 2018 – 2032 73

FIG NO. 45. U.S. Biomaterials Market for Dental, Revenue (USD Million) 2018 – 2032 74

FIG NO. 46. U.S. Biomaterials Market for Neurology, Revenue (USD Million) 2018 – 2032 75

FIG NO. 47. U.S. Biomaterials Market for Tissue Engineering, Revenue (USD Million) 2018 – 2032 76

FIG NO. 48. U.S. Biomaterials Market for Others, Revenue (USD Million) 2018 – 2032 77

List of Tables

TABLE NO. 1. : U.S. Biomaterials Market: Snapshot 20

TABLE NO. 2. : Drivers for the U.S. Biomaterials Market: Impact Analysis 24

TABLE NO. 3. : Restraints for the U.S. Biomaterials Market: Impact Analysis 26

TABLE NO. 4. : U.S. Biomaterials Market Revenue, By Product Type, 2018 – 2023 (USD Million) 78

TABLE NO. 5. : U.S. Biomaterials Market Revenue, By Product Type, 2024 – 2032 (USD Million) 78

TABLE NO. 6. : U.S. Biomaterials Market Revenue, By Application, 2018 – 2023 (USD Million) 79

TABLE NO. 7. : U.S. Biomaterials Market Revenue, By Application, 2024 – 2032 (USD Million) 79

Frequently Asked Questions

What is the current size of the U.S. Biomaterials?

The market size was USD 64,865.73 million in 2024, projected to reach USD 198,681.66 million by 2032.

What factors are driving the growth of the U.S. Biomaterials?

Key drivers include aging population, chronic disease prevalence, 3D printing innovations, and government-backed R&D.

What are some challenges faced by the U.S. Biomaterials?

High production costs and complex regulatory approval processes limit scalability and market entry.

Who are the major players in the U.S. Biomaterials?

Leading companies include Johnson & Johnson, Stryker, Baxter International, Biomet, and Smith & Nephew.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –